Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Oct
23
Today In Oncology
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo